DYSPEPSIA AND DISEASE BURDEN AMONG PATIENTS WITH ATRIAL FIBRILLATION (AF)
Author(s)
LaMori JC1, Gross HJ2, Patel AA1, Crain M3, DiBonaventura MD2, Mody SH1, Schein J11Ortho-McNeil Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Kantar Health, New York, NY, USA, 3Centocor Ortho Biotech Services, LLC, Virginia Beach, VA, USA
OBJECTIVES: Many agents used in treating AF have potential gastrointestinal (GI) tolerability issues. Treatment-related adverse GI events are a common reason for noncompliance to treatment. The current analysis describes the prevalence of dyspepsia in relation to anticoagulant use among AF patients. METHODS: Data were obtained from the 2009 National Health and Wellness Survey (N=75,000), an annual cross-sectional Internet-based survey of US adults. Respondents answered general demographic and health-related questions. A CHADS2 score (an index of stroke risk) was calculated for each patient using demographic and clinical characteristics. RESULTS: A total of 1297 patients (1.7%) reported a diagnosis of AF. Of these patients, 535 (41%) also reported a physician-diagnosed GI condition; 449 of these (84%) were consistent with dyspepsia (ulcers, abdominal bloating, abdominal pain, gastroesophageal reflux disease/acid reflux, or heartburn). Compared with AF patients without dyspepsia (n=848), those with dyspepsia were younger (mean 62.9 vs. 66.0 years, p<0.05) and more likely to be female (43% vs. 31%, p<0.05). AF patients with dyspepsia were in poorer health than those without dyspepsia, as evidenced by a higher CHADS2 score (1.9 vs. 1.4, p<0.05); this difference was more pronounced in patients aged >65 years and in those with CHADS2 score >2. Despite this, significantly fewer AF patients with than without dyspepsia were taking a prescription medication to treat AF (67% vs. 73%, p<0.05) or an anticoagulant for stroke prevention (35% vs. 47%, p<0.05). CONCLUSIONS: One-third of AF patients in this analysis had dyspepsia. These patients reported a greater disease burden and stroke risk relative to AF patients without dyspepsia. Significantly fewer AF patients with than those without dyspepsia were taking a prescription to treat AF or an anticoagulant for stroke prevention. Poor GI tolerability may be significant in the AF population and should be considered when adherence to medication is critical, such as in high-risk populations.
Conference/Value in Health Info
2011-05, ISPOR 2011, Baltimore, MD, USA
Value in Health, Vol. 14, No. 3 (May 2011)
Code
PCV14
Topic
Epidemiology & Public Health
Disease
Cardiovascular Disorders, Gastrointestinal Disorders, Respiratory-Related Disorders